Unexpected large-vessel vasculitis in colon adenocarcinoma treated with bevacizumab

Bevacizumab, although generally well tolerated, can, in rare cases, cause large-vessel vasculitis, even in the absence of concomitant granulocyte colony-stimulating factor therapy.Clinical presentation of drug-induced aortitis may be subtle or asymptomatic, and imaging studies such as ¹⁸F-fluorodeoxyglucose positron emission tomography or magnetic resonance angiography play a key role in diagnosis.Recognition and prompt reporting of unexpected vascular toxicities are essential for pharmacovigilance, particularly as antiangiogenic agents become increasingly used in oncologic treatment regimens.